Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Aandeel ProQR Therapeutics NV OTC:PRQR.Q, NL0010872495

  • 8,240 16 sep 2021 22:00
  • -0,030 (-0,36%) Dagrange 8,000 - 8,310
  • 280.821 Gem. (3M) 683,4K

ProQR Therapeutics 2020

873 Posts
Pagina: «« 1 ... 39 40 41 42 43 44 »» | Laatste | Omlaag ↓
  1. evenaar 19 december 2020 16:19
    We gaan het zien. Geen nieuws, alleen een paar grote ver/aankopen onder de 4 dollar. En nu weer net boven de 4.

    Gisteren voor de omzetstijging de laatste pluk verkocht. Hopende dat iemand met een paar tiental K de koers weer lager ging zetten. Is niet gebeurd. Sterker het tegenovergestelde.
    Maandag maar eens kijken of er nog een instapmoment is.

    Met een beetje pech een hoger opening. Dan was blijven zitten beter.
    Als particulier zonder informatie is de gokfactor behoorlijk.

  2. forum rang 6 harvester 20 december 2020 19:26
    quote:

    wist ik het maar schreef op 19 december 2020 12:51:


    =Will73

    Hopelijk iets goeds te melden !


    vreemd vlak einde heel veel omzet bij proqr
    wat de koers flink deed op lopen
    kan niet echt nieuws hier over vinden


    Helaas vind ik ook niets. Wellicht is het gewoon een verhanging tussen 2 fondsen van een fondsmanager of het realiseren door een Amerikaanse belegger van een fiscaal aftrekbaar verlies, gevolgd door een terugkoop. In elk geval lijkt dit positief.
  3. Missolapola 20 december 2020 20:32
    quote:

    wist ik het maar schreef op 19 december 2020 12:51:


    =Will73

    Hopelijk iets goeds te melden !


    vreemd vlak einde heel veel omzet bij proqr
    wat de koers flink deed op lopen
    kan niet echt nieuws hier over vinden


    ProQR wordt uit de NBI gehaald vanaf morgen, zal dus wellicht verkoop/aankoop in dat licht geweest zijn

    Annual Changes to the Nasdaq Biotechnology Index

    December 11, 2020 20:05 ET | Source: Nasdaq, Inc.
    NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.

    The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
  4. J@@p11 21 januari 2021 17:49
    TipRanks

    Thu, January 21, 2021, 4:34 PM

    ProQR (PRQR)

    ProQR is a biotechnology company focused on treatments for congenital progressive blindness. Specifically, the firm is working on medications to reverse a group of genetic sight disorders called inherited retinal diseases. These diseases currently have no effective treatments.

    The company has a research pipeline of five drug candidates, in varying stages of the research process. The two that are farthest along are QR-110 (Sepofarsen), and QR-421. Of those two, QR-110 is currently in Phase 2/3 studies. This candidate is an RNA therapy designed to correct the most common CEP290 gene mutation causing Leber congenital amaurosis 10 (LCA10). This is a severe genetic retinal disease that affects as many as 3 in 100,000 children.

    QR-421 is another RNA therapy, this one focused on exon 13 mutations in the USH2A gene. These mutations cause blindness due to retinitis pigmentosa and/or Usher syndrome. QR-421 is in Phase 1/2 studies, with an aim of restoring lost vision or preventing the loss in the first place.

    Covering the stock for JMP, analyst Jonathan Wolleben points to Sepofarsen as a key component of his bullish thesis.

    “We continue to feel good about sepofarsen’s chance of success in Illuminate for multiple reasons: 1) Phase 1/2 confirmed the target registrational dose and dosing interval (6 months); 2) patients had clinically significant and durable BCVA improvements after 12 months – pivotal primary endpoint; 3) supportive secondary efficacy measures (FST, mobility); 4) similar responses seen in second treated eyes; 5) long-term safety confirms positive risk/benefit; and 6) Illuminate patient population was enriched based on Phase 1/2 results (baselinevision of >/=hand motion). We assign sepofarsen a 60% POS and model LCA10 as an ~$300M opportunity to PRQR at peak penetration," Wolleben opined.

    In line with his upbeat outlook, Wolleben puts a $20 price target on the stock, implying a 384% one-year upside, along with an Outperform (i.e. Buy) rating. (To watch Wolleben’s track record, click here)

    All in all, PRQR gets a unanimous Strong Buy rating from the analyst consensus, based on 3 positive stock reviews. Shares are currently trading for $4.13, and their $20.67 average price target is slightly more bullish than Wolleben’s, suggesting an upside of 400% for the coming 12 months. (See PRQR stock analysis at TipRanks)
  5. Missolapola 17 februari 2021 08:14
    ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that the Company will host an Expert Perspectives call on February 22, 2021 at 12:00pm EST. The call will feature a discussion between Aniz Girach, MD, Chief Medical Officer of ProQR Therapeutics and Paul Yang, MD, PhD about disease education and endpoints in Usher syndrome and non-syndromic Retinitis Pigmentosa (nsRP). Areas of focus for the session will include which vision measures are most informative in the context of this disease setting, the role of patient baseline and disease progression, and an overview of the objectives of the Phase 1/2 Stellar trial of QR-421a.

    Continue reading this press release
873 Posts
Pagina: «« 1 ... 39 40 41 42 43 44 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

ProQR Therapeutics NV Meer »

Koers 8,240   Verschil -0,03 (-0,36%)
Laag 8,000   Volume 280.821
Hoog 8,310   Gem. Volume 683.445
16 sep 2021 22:00
label premium

KOPEN OF VERKOPEN?

Het laatste advies leest u als IEX Premium-lid

Ontdek Premium

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links